Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.92%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Receivables (2021 - 2023)

Updated

Inhibikase Therapeutics' Receivables came in at $79,604 for Q2 2023, compared with $6,552 a year earlier and up 23.4% from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Receivables (2021 - 2023) Analysis & Trends

At the end of FY2022, Inhibikase Therapeutics' Receivables was $39,881, down 63.8% from FY2021.

  • Going back by year, Receivables was $110,141 in FY2021.
  • The Q2 2023 figure represents the highest quarterly Receivables since Q4 2021.
  • Business Quant data shows IKT's Receivables at $64,521 (Q1 2023), $39,881 (Q4 2022) and $13,842 (Q3 2022) in the three quarters before Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 79,604.00
Mar 31, 2023 64,521.00
Dec 31, 2022 39,881.00
Sep 30, 2022 13,842.00
Jun 30, 2022 6,552.00
Mar 31, 2022 47,976.00
Dec 31, 2021 110,141.00
API Access

Inhibikase Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=IKT&period=max&api_key=YOUR_API_KEY